LAUSR

1. Menard A, Montagnac C, Solas C, et al. Neuropsychiatric adverse effects on dolutegravir: an emerging concern in Europe. AIDS 2017(in press). 2. Achra AC et al. Body mass index and the risk of serious non-AIDS events [Abstract 693]. 24th Conference on Retroviruses and opportunistic infections (CROI), 13–16 February 2017. 3. Plankey M, Bacchetti P, Jin C, Grimes B, Hyman C, Cohen M, et al. Self-perception of body fat changes and HAART adherence in the Women’s Interagency HIV study. AIDS Behav 2009; 13:53–59. 4. McComsey GA, Moser C, Currier J, Ribaudo HJ, Paczuski P, Dubé MP, et al. Body composition changes after initiation of raltegravir or protease inhibitors: ACTG A5260s. Clin Infect Dis 2016; 62:853–862. 5. Moure R, Domingo P, Gallego-Escuredo JM, Villarroya J, Gutierrez Mdel M, Mateo MG, et al. Impact of elvitegravir on human adipocytes: alterations in differentiation, gene expression and release of adipokines and cytokines. Antiviral Res 2016; 132:59–65.